Reuters logo
BRIEF-Immunicum announces completion of HCC Phase I/II clinical study‍​
September 28, 2017 / 6:07 AM / 3 months ago

BRIEF-Immunicum announces completion of HCC Phase I/II clinical study‍​

Sept 28 (Reuters) - IMMUNICUM AB ‍​

* REG-IMMUNICUM AB (PUBL) ANNOUNCES COMPLETION OF HCC PHASE I/II CLINICAL STUDY

* ‍ANNOUNCES POSITIVE TOPLINE RESULTS FROM COMPLETED PHASE I/II SAFETY, TOLERABILITY CLINICAL TRIAL OF ILIXADENCEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below